Experience of the use of zoledronic acid (Rezoklastin 5 mg/6.25 ml, OOO «NATIVA») in patients with low bone mineral density in the settings of the center for prevention of osteoporosis of Novosibirsk SRITO


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The purpose of this work was to evaluate bone mineral density (BMD) at 2, 3, 4, 5 and 6 years of the use of zoledronic acid (Rezoklastin 5 mg/6.25 mL) in patients with osteopenia and osteoporosis. We examined 60 postmenopausal women aged 48-76 with low BMD (T-criterion from -2.6 to -4.5 SD). The following basic methods of research were used: clinical; sociological; X-ray; densitometric (osteodensitometer HOLOGIC, QDR, Discovery-A, USA); and statistical methods. The main results of the work were good tolerability of the drug; absence of fractures during observation period; an increase in BMD in all patient groups and across all regions.

Толық мәтін

Рұқсат жабық

Авторлар туралы

E. Kulyaev

FSBI SRI of Traumatology and Orthopedics n.a Ya.L. Tsivyan of RMH

Email: EKulyaev@niito.ru
Junior Researcher, Traumatologist-Orthopedist at the Center for the Prevention of Osteoporosis

A. Grafov

FSBI SRI of Traumatology and Orthopedics n.a Ya.L. Tsivyan of RMH

O. Falameeva

FSBI SRI of Traumatology and Orthopedics n.a Ya.L. Tsivyan of RMH

V. Kholodkin

FSBI SRI of Traumatology and Orthopedics n.a Ya.L. Tsivyan of RMH

M. Sadovoy

FSBI SRI of Traumatology and Orthopedics n.a Ya.L. Tsivyan of RMH; SBEI HPE Novosibirsk State Medical University of RMH

O. Tsygankova

SBEI HPE Novosibirsk State Medical University of RMH

Әдебиет тізімі

  1. Инструкция по медицинскому применению препарата Резокластин гос. № ЛСР- 003578/10.
  2. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Guide S., Wu W., Mangood A., Russell R.G., Ebetino F.H. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006;38(5):617-27.
  3. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., Ebetino F.H., Rogers M.J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogencontaining bisphosphonates. J. Pharmacol. Exp. Ther. 2001;296:235-42.
  4. Rogers M.J., Frith J.C., Luckman S.P. et al. Molecular mechanisms of action of bisphosphonates. Bone. 1999 (Suppl. 5):73-9.
  5. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19:80-100
  6. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., Golub E., Rodan G.A. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. 1991;88:2095-105.
  7. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 2003;9(32):2643-58.
  8. Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D., Mundy G.R., Boyce B.F Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 1995;10:1478-87.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2017

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>